KENNETH S SHARLIN
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine
- Where
- OZARK, MO
- NPI
- 1790749182
- Received
- $145,364 in 818 records, 2019 to 2025 ($38,447 general, $106,917 research)
- As principal investigator
- $4,185,937 of research payments to others in 183 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 95 | $3,115 |
| 2025 | Research payment | 2 | $13,800 |
| 2024 | General payment | 130 | $3,685 |
| 2023 | General payment | 174 | $3,398 |
| 2023 | Research payment | 7 | $13,267 |
| 2022 | General payment | 140 | $5,499 |
| 2022 | Research payment | 2 | $4,235 |
| 2021 | General payment | 120 | $13,792 |
| 2021 | Research payment | 4 | $75,615 |
| 2020 | General payment | 111 | $8,281 |
| 2019 | General payment | 33 | $675 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 15 | $106,917 |
| Food and Beverage | 775 | $14,693 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 9 | $13,900 |
| Travel and Lodging | 12 | $4,860 |
| Consulting Fee | 1 | $2,825 |
| Education | 6 | $2,168 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-18 | GENZYME CORPORATION | $29 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-09 | Janssen Biotech, Inc. | $37 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-09 | Vanda Pharmaceuticals Inc. | $27 | Food and Beverage | In-kind items and services | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-12-04 | Genentech USA, Inc. | $16 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2025 | |
| 2025-12-02 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-12-02 | TG Therapeutics, Inc. | $13 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-11-21 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-11-18 | EMD Serono, Inc. | $16 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-17 | Supernus Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | Qelbree Drug, VILOXAZINE HYDROCHLORIDE | 2025 | |
| 2025-11-17 | Supernus Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | Qelbree Drug, VILOXAZINE HYDROCHLORIDE | 2025 | |
| 2025-11-12 | Eisai Inc. | $24 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-11-12 | Amneal Pharmaceuticals LLC | $20 | Food and Beverage | In-kind items and services | CREXONT Drug, NEUROLOGY | 2025 | |
| 2025-11-10 | Otsuka America Pharmaceutical, Inc. | $18 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-11-03 | Mallinckrodt Hospital Products Inc. | $22 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-10-31 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-10-30 | SK Life Science, Inc. | $25 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-28 | Celgene Corporation | $15 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-10-27 | PFIZER INC. | $10 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-10-27 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-10-24 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-10-16 | GENZYME CORPORATION | $84 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-14 | GENZYME CORPORATION | $30 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-13 | ANI Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | PURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | 2025 | |
| 2025-10-10 | Tanabe Pharma America, Inc. | $14 | Food and Beverage | In-kind items and services | Radicava Drug, Not Applicable | 2025 | |
| 2025-10-07 | Vanda Pharmaceuticals Inc. | $18 | Food and Beverage | In-kind items and services | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-09-25 | Eisai Inc. | $19 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-09-25 | Otsuka America Pharmaceutical, Inc. | $15 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-09-15 | Teva Pharmaceuticals USA, Inc. | $15 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-09-09 | Takeda Pharmaceuticals U.S.A., Inc. | $28 | Food and Beverage | In-kind items and services | HYQVIA Biological, IMMUNOLOGY | 2025 | |
| 2025-09-08 | ARGENX US, INC. | $19 | Food and Beverage | In-kind items and services | VYVGART HYTRULO Drug, Neurology | 2025 | |
| 2025-09-03 | Amneal Pharmaceuticals LLC | $15 | Food and Beverage | In-kind items and services | CREXONT Drug, NEUROLOGY | 2025 | |
| 2025-08-26 | Vanda Pharmaceuticals Inc. | $28 | Food and Beverage | In-kind items and services | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-08-25 | PFIZER INC. | $12 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-08-14 | Eisai Inc. | $21 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-08-12 | Teva Pharmaceuticals USA, Inc. | $16 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-08-05 | Celgene Corporation | $18 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-08-04 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-07-31 | Eisai Inc. | $20 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-07-24 | GENZYME CORPORATION | $36 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-24 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-07-23 | Lilly USA, LLC | $20 | Food and Beverage | In-kind items and services | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-07-22 | Amneal Pharmaceuticals LLC | $6,900 | Research payment | Cash or cash equivalent | CREXONT Drug, NEUROLOGY | IPX203-401-23 | 2025 |
| 2025-07-22 | Amneal Pharmaceuticals LLC | $6,900 | Research payment | Cash or cash equivalent | CREXONT Drug, NEUROLOGY | IPX203-401-23 | 2025 |
| 2025-07-22 | E.R. Squibb & Sons, L.L.C. | $1,177 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-07-22 | Neurocrine BioSciences, Inc. | $24 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-07-21 | Amneal Pharmaceuticals LLC | $11 | Food and Beverage | In-kind items and services | CREXONT Drug, NEUROLOGY | 2025 | |
| 2025-07-15 | GENZYME CORPORATION | $36 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-14 | Teva Pharmaceuticals USA, Inc. | $19 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-07-08 | EMD Serono, Inc. | $14 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-07-03 | Genentech USA, Inc. | $29 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2025 | |
| 2025-06-26 | Eisai Inc. | $32 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-06-17 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-06-16 | Genentech USA, Inc. | $15 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2025 | |
| 2025-06-11 | Lilly USA, LLC | $21 | Food and Beverage | In-kind items and services | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-06-05 | Novartis Pharmaceuticals Corporation | $30 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-06-04 | Vanda Pharmaceuticals Inc. | $29 | Food and Beverage | In-kind items and services | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-06-02 | Mallinckrodt Hospital Products Inc. | $22 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-05-28 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-05-27 | Teva Pharmaceuticals USA, Inc. | $19 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-05-21 | Eisai Inc. | $22 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-05-20 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-05-19 | ACADIA Pharmaceuticals Inc | $20 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-05-09 | Lundbeck LLC | $17 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2025 | |
| 2025-05-02 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-04-28 | ACADIA Pharmaceuticals Inc | $20 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-04-24 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | ZAVZPRET Drug, PAIN | 2025 | |
| 2025-04-22 | EMD Serono, Inc. | $17 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-04-21 | Teva Pharmaceuticals USA, Inc. | $17 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-04-18 | PFIZER INC. | $9 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-04-17 | Eisai Inc. | $30 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-04-15 | TG Therapeutics, Inc. | $27 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-04-11 | Genentech USA, Inc. | $16 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2025 | |
| 2025-04-02 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-04-01 | Neurocrine BioSciences, Inc. | $17 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-03-28 | Genentech USA, Inc. | $30 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2025 | |
| 2025-03-27 | TG Therapeutics, Inc. | $23 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-03-25 | Eisai Inc. | $18 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-03-24 | Lundbeck LLC | $22 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2025 | |
| 2025-03-13 | EMD Serono, Inc. | $18 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-03-13 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-03-10 | SK Life Science, Inc. | $20 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-06 | MDD US Operations, LLC | $24 | Food and Beverage | In-kind items and services | Gocovri Drug, AMANTADINE | 2025 | |
| 2025-03-04 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-03-03 | Teva Pharmaceuticals USA, Inc. | $18 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-02-25 | TG Therapeutics, Inc. | $24 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-02-24 | PFIZER INC. | $12 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-02-24 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-02-11 | Lilly USA, LLC | $25 | Food and Beverage | In-kind items and services | KISUNLA Drug, Neuroscience | 2025 | |
| 2025-02-04 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-01-30 | Eisai Inc. | $23 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-01-28 | EMD Serono, Inc. | $20 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-01-27 | Teva Pharmaceuticals USA, Inc. | $16 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-01-21 | JAZZ PHARMACEUTICALS INC. | $25 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-01-17 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-01-15 | PFIZER INC. | $12 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-01-13 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2025 | |
| 2025-01-09 | Celgene Corporation | $18 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2024-12-19 | Neurocrine BioSciences, Inc. | $2 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-12-18 | Neurocrine BioSciences, Inc. | $18 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-12-17 | EMD Serono, Inc. | $22 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-12-05 | Novartis Pharmaceuticals Corporation | $28 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-11-26 | Eisai Inc. | $26 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2024 | |
| 2024-11-25 | EMD Serono, Inc. | $19 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-11-25 | Lundbeck LLC | $15 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2024 | |
| 2024-11-25 | Lundbeck LLC | $2 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2024 | |
| 2024-11-22 | Genentech USA, Inc. | $17 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2024 | |
| 2024-11-21 | Neurocrine BioSciences, Inc. | $25 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-11-18 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | ZAVZPRET Drug, PAIN | 2024 | |
| 2024-11-12 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-11-12 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-11-07 | Teva Pharmaceuticals USA, Inc. | $18 | Food and Beverage | In-kind items and services | Austedo XR Drug, Central Nervous System | 2024 | |
| 2024-11-05 | MDD US Operations, LLC | $13 | Food and Beverage | In-kind items and services | Gocovri Drug, AMANTADINE | 2024 | |
| 2024-11-01 | Lundbeck LLC | $18 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2024 | |
| 2024-10-29 | Eisai Inc. | $28 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2024 | |
| 2024-10-24 | Eisai Inc. | $22 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2024 | |
| 2024-10-24 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2024 | |
| 2024-10-21 | Tanabe Pharma America, Inc. | $17 | Food and Beverage | In-kind items and services | RADICAVA Drug, AMYOTROPHIC LATERAL SCLEROSIS | 2024 | |
| 2024-10-18 | EMD Serono, Inc. | $14 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-10-14 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-10-09 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-10-03 | Genentech USA, Inc. | $15 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2024 | |
| 2024-10-02 | GENZYME CORPORATION | $27 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-30 | Teva Pharmaceuticals USA, Inc. | $18 | Food and Beverage | In-kind items and services | Austedo XR Drug, Central Nervous System | 2024 | |
| 2024-09-24 | EMD Serono, Inc. | $16 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-09-23 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2024 | |
| 2024-09-19 | PFIZER INC. | $12 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-09-18 | Eisai Inc. | $25 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2024 | |
| 2024-09-13 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-09-10 | Lundbeck LLC | $13 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2024 | |
| 2024-09-09 | TG Therapeutics, Inc. | $24 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2024 | |
| 2024-09-05 | PFIZER INC. | $11 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-09-04 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-09-04 | Novartis Pharmaceuticals Corporation | $7 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-09-03 | Celgene Corporation | $23 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2024 | |
| 2024-08-28 | Neurocrine BioSciences, Inc. | $3 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-08-27 | Lilly USA, LLC | $23 | Food and Beverage | In-kind items and services | KISUNLA Drug, Neuroscience | 2024 | |
| 2024-08-27 | Neurocrine BioSciences, Inc. | $22 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-08-21 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2024 | |
| 2024-08-20 | Eisai Inc. | $25 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2024 | |
| 2024-08-19 | Teva Pharmaceuticals USA, Inc. | $17 | Food and Beverage | In-kind items and services | Austedo XR Drug, Central Nervous System | 2024 | |
| 2024-08-15 | Mallinckrodt Hospital Products Inc. | $31 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2024 | |
| 2024-08-14 | Tanabe Pharma America, Inc. | $15 | Food and Beverage | In-kind items and services | RADICAVA Drug, AMYOTROPHIC LATERAL SCLEROSIS | 2024 | |
| 2024-08-10 | MDD US Operations, LLC | $22 | Food and Beverage | In-kind items and services | Gocovri Drug, AMANTADINE | 2024 | |
| 2024-08-10 | EMD Serono, Inc. | $18 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-08-01 | Lilly USA, LLC | $6 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2024 | |
| 2024-07-31 | EMD Serono, Inc. | $23 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-07-29 | Genentech USA, Inc. | $17 | Food and Beverage | In-kind items and services | Enspryng Biological, Immunology | 2024 | |
| 2024-07-24 | Neurocrine BioSciences, Inc. | $22 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-07-23 | Alexion Pharmaceuticals, Inc. | $27 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-07-22 | Lilly USA, LLC | $3 | Food and Beverage | In-kind items and services | KISUNLA Drug, Neuroscience | 2024 | |
| 2024-07-19 | PFIZER INC. | $9 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-07-17 | Eisai Inc. | $25 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2024 | |
| 2024-07-16 | Celgene Corporation | $14 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2024 | |
| 2024-07-15 | Lilly USA, LLC | $21 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2024 | |
| 2024-07-12 | Biogen, Inc. | $16 | Food and Beverage | In-kind items and services | QALSODY Drug, Neurology | 2024 | |
| 2024-07-11 | Lundbeck LLC | $16 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2024 | |
| 2024-07-09 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-06-27 | EMD Serono, Inc. | $17 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-06-24 | ARGENX US, INC. | $16 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2024 | |
| 2024-06-21 | Neurocrine BioSciences, Inc. | $22 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-06-20 | Neurocrine BioSciences, Inc. | $5 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-06-17 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2024 | |
| 2024-06-13 | Lilly USA, LLC | $19 | Food and Beverage | In-kind items and services | AMYVID Drug, Neuroscience | 2024 | |
| 2024-06-13 | PFIZER INC. | $10 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-06-10 | Novartis Pharmaceuticals Corporation | $26 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-06-04 | Tanabe Pharma America, Inc. | $15 | Food and Beverage | In-kind items and services | RADICAVA Drug, AMYOTROPHIC LATERAL SCLEROSIS | 2024 | |
| 2024-06-03 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-05-30 | LivaNova USA, Inc. | $22 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2024 | |
| 2024-05-28 | Genentech USA, Inc. | $16 | Food and Beverage | In-kind items and services | Ocrevus Biological, Immunology | 2024 | |
| 2024-05-23 | Amneal Pharmaceuticals LLC | $19 | Food and Beverage | In-kind items and services | ONGENTYS Drug, NEUROLOGY | 2024 | |
| 2024-05-22 | Lilly USA, LLC | $21 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2024 | |
| 2024-05-20 | Teva Pharmaceuticals USA, Inc. | $19 | Food and Beverage | In-kind items and services | Austedo XR Drug, Central Nervous System | 2024 | |
| 2024-05-20 | Lundbeck LLC | $15 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2024 | |
| 2024-05-17 | PFIZER INC. | $10 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-05-14 | Novartis Pharmaceuticals Corporation | $32 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-05-09 | Neurocrine BioSciences, Inc. | $26 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-05-08 | EMD Serono, Inc. | $16 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-05-07 | KYOWA KIRIN, INC. | $20 | Food and Beverage | In-kind items and services | Nourianz Drug, Adenosine A2A Receptors | 2024 | |
| 2024-05-01 | Celgene Corporation | $24 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2024 | |
| 2024-04-25 | GE HEALTHCARE | $19 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-25 | Abbott Laboratories | $14 | Food and Beverage | In-kind items and services | ETERNA Device, Neuromodulation | 2024 | |
| 2024-04-23 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-04-23 | ANI Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | PURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | 2024 | |
| 2024-04-19 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-04-18 | EMD Serono, Inc. | $20 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-04-17 | Lilly USA, LLC | $20 | Food and Beverage | In-kind items and services | AMYVID Drug, Neuroscience | 2024 | |
| 2024-04-17 | PFIZER INC. | $7 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-04-15 | Lundbeck LLC | $16 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2024 | |
| 2024-04-11 | Neurocrine BioSciences, Inc. | $25 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-04-11 | Neurocrine BioSciences, Inc. | $22 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-04-10 | Neurocrine BioSciences, Inc. | $130 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-04-10 | Neurocrine BioSciences, Inc. | $6 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-04-08 | Mallinckrodt Hospital Products Inc. | $13 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2024 | |
| 2024-04-04 | Teva Pharmaceuticals USA, Inc. | $19 | Food and Beverage | In-kind items and services | Austedo XR Drug, Central Nervous System | 2024 | |
| 2024-03-29 | E.R. Squibb & Sons, L.L.C. | $778 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-03-29 | E.R. Squibb & Sons, L.L.C. | $328 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-03-29 | E.R. Squibb & Sons, L.L.C. | $173 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-03-26 | Novartis Pharmaceuticals Corporation | $19 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-03-25 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2024 | |
| 2024-03-20 | KYOWA KIRIN, INC. | $19 | Food and Beverage | In-kind items and services | Nourianz Drug, Adenosine A2A Receptors | 2024 |
The latest 200 records of 818.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | ABBVIE INC. | INFINITE RESEARCH GROUP LLC | $1,440 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safe | 2025 |
| 2025-12-22 | GENZYME CORPORATION | Sharlin Health And Neurology | $10,779 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-12-11 | ABBVIE INC. | INFINITE RESEARCH GROUP LLC | $660 | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai | 2025 |
| 2025-11-24 | PFIZER INC. | SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $4,110 | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT | 2025 |
| 2025-11-12 | Hoffmann-La Roche Limited | INFINITE RESEARCH GROUP LLC | $2,593 | A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple S | 2025 |
| 2025-11-05 | Eli Lilly and Company | INFINITE RESEARCH GROUP LLC | $59,012 | AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LY3541 | 2025 |
| 2025-11-04 | GENZYME CORPORATION | INFINITE RESEARCH GROUP LLC | $70,469 | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2025 |
| 2025-10-24 | GENZYME CORPORATION | INFINITE RESEARCH GROUP LLC | $14,002 | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2025 |
| 2025-10-17 | ModernaTX, Inc. | Sharlin Health & Neurology | $66 | A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 1 | 2025 |
| 2025-10-09 | ABBVIE INC. | INFINITE RESEARCH GROUP LLC | $100 | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Ch | 2025 |
| 2025-10-08 | Hoffmann-La Roche Limited | INFINITE RESEARCH GROUP LLC | $1,730 | A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple S | 2025 |
| 2025-10-08 | Hoffmann-La Roche Limited | INFINITE RESEARCH GROUP LLC | $7,102 | A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple S | 2025 |
| 2025-10-08 | Hoffmann-La Roche Limited | INFINITE RESEARCH GROUP LLC | $3,500 | A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple S | 2025 |
| 2025-09-04 | ABBVIE INC. | INFINITE RESEARCH GROUP LLC | $4,266 | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai | 2025 |
| 2025-09-03 | GENZYME CORPORATION | Sharlin Health And Neurology | $12,905 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2025 |
| 2025-08-25 | GENZYME CORPORATION | Sharlin Health And Neurology | $7,173 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-08-06 | ModernaTX, Inc. | Sharlin Health & Neurology | $624 | A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 1 | 2025 |
| 2025-08-06 | ModernaTX, Inc. | Sharlin Health & Neurology | $12,486 | A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 1 | 2025 |
| 2025-08-06 | ModernaTX, Inc. | Sharlin Health & Neurology | $957 | A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 1 | 2025 |
| 2025-07-29 | PFIZER INC. | SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $2,549 | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIM | 2025 |
| 2025-07-02 | ModernaTX, Inc. | Sharlin Health & Neurology | $17 | A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 1 | 2025 |
| 2025-07-02 | ModernaTX, Inc. | Sharlin Health & Neurology | $66 | A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 1 | 2025 |
| 2025-06-25 | E.R. Squibb & Sons, L.L.C. | SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $18,338 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Kar | 2025 |
| 2025-05-27 | Eli Lilly and Company | SHARLIN HEALTH AND NEUROLOGY LLC | $56 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2025 |
| 2025-04-28 | GENZYME CORPORATION | Sharlin Health And Neurology | $14,336 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-04-14 | GENZYME CORPORATION | Sharlin Health And Neurology | $10,350 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2025 |
| 2025-03-06 | ABBVIE INC. | SHARLIN HLTH NEUROSCIENCE RESH CNTR | $366 | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai | 2025 |
| 2025-03-05 | Eli Lilly and Company | SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $17,147 | AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LY3541 | 2025 |
| 2025-02-24 | GENZYME CORPORATION | Sharlin Health And Neurology | $5,008 | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa | 2025 |
| 2025-02-24 | GENZYME CORPORATION | Sharlin Health And Neurology | $9,320 | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa | 2025 |
| 2025-02-05 | ABBVIE INC. | SHARLIN HLTH NEUROSCIENCE RESH CNTR | $366 | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai | 2025 |
| 2025-01-27 | GENZYME CORPORATION | Sharlin Health And Neurology | $2,036 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-01-21 | Eli Lilly and Company | SHARLIN HEALTH AND NEUROLOGY LLC | $8,055 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2025 |
| 2025-01-16 | Eli Lilly and Company | SHARLIN HEALTH AND NEUROLOGY LLC | $1,146 | AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LY3541 | 2025 |
| 2025-01-13 | GENZYME CORPORATION | Sharlin Health And Neurology | $9,817 | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2025 |
| 2025-01-02 | ABBVIE INC. | SHARLIN HLTH NEUROSCIENCE RESH CNTR | $1,686 | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai | 2025 |
| 2024-12-31 | ABBVIE INC. | SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $1,440 | 3110-305-002 Ph3 Pivotal Peds Post Approval - PMR (M21-265) | 2024 |
| 2024-12-18 | Eli Lilly and Company | SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $3,600 | LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH | 2024 |
| 2024-12-17 | Novartis Pharmaceuticals Corporation | Sharlin Health And Neurology | $19 | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat | 2024 |
| 2024-12-04 | ABBVIE INC. | SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $366 | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai | 2024 |
| 2024-12-04 | Eli Lilly and Company | SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $15,000 | AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LY3541 | 2024 |
| 2024-12-03 | GENZYME CORPORATION | Sharlin Health And Neurology | $1,913 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-11-12 | GENZYME CORPORATION | Sharlin Health And Neurology | $901 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2024 |
| 2024-11-12 | GENZYME CORPORATION | Sharlin Health And Neurology | $6,749 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2024 |
| 2024-11-12 | GENZYME CORPORATION | Sharlin Health And Neurology | $1,913 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-11-06 | ABBVIE INC. | SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $365 | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai | 2024 |
| 2024-11-06 | Hoffmann-La Roche Limited | SHARLIN HEALTH AND NEUROLOGY LLC | $16,008 | Fen Ph II RMS | 2024 |
| 2024-10-28 | GENZYME CORPORATION | Sharlin Health And Neurology | $9,211 | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2024 |
| 2024-10-28 | Eli Lilly and Company | SHARLIN HEALTH AND NEUROLOGY LLC | $109 | LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH | 2024 |
| 2024-09-04 | GENZYME CORPORATION | Sharlin Health And Neurology | $2,680 | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2024 |
| 2024-09-04 | GENZYME CORPORATION | Sharlin Health And Neurology | $11,400 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2024 |
| 2024-09-04 | GENZYME CORPORATION | Sharlin Health And Neurology | $9,500 | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participa | 2024 |
| 2024-09-04 | GENZYME CORPORATION | Sharlin Health And Neurology | $10,350 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-09-04 | GENZYME CORPORATION | Sharlin Health And Neurology | $12,000 | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2024 |
| 2024-09-03 | ABBVIE INC. | SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $366 | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai | 2024 |
| 2024-08-19 | GENZYME CORPORATION | Sharlin Health And Neurology | $4,000 | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2024 |
| 2024-08-15 | PFIZER INC. | SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $2,544 | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT | 2024 |
| 2024-08-12 | GENZYME CORPORATION | Sharlin Health And Neurology | $12,178 | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2024 |
| 2024-08-01 | ABBVIE INC. | SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $2,052 | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai | 2024 |
| 2024-07-29 | GENZYME CORPORATION | Sharlin Health And Neurology | $5,360 | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2024 |
| 2024-07-25 | Eli Lilly and Company | SHARLIN HEALTH AND NEUROLOGY LLC | $1,888 | AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LY3541 | 2024 |
| 2024-07-22 | GENZYME CORPORATION | Sharlin Health And Neurology | $2,036 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-07-03 | ABBVIE INC. | SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $630 | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai | 2024 |
| 2024-07-03 | Hoffmann-La Roche Limited | SHARLIN HEALTH AND NEUROLOGY LLC | $16,334 | Fen Ph II RMS | 2024 |
| 2024-06-10 | GENZYME CORPORATION | Sharlin Health And Neurology | $1,913 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-06-05 | ABBVIE INC. | SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $6,705 | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Ch | 2024 |
| 2024-06-05 | ABBVIE INC. | SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $4,022 | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai | 2024 |
| 2024-05-28 | GENZYME CORPORATION | Sharlin Health And Neurology | $1,248 | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2024 |
| 2024-05-23 | PFIZER INC. | SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $836 | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT | 2024 |
| 2024-05-08 | ABBVIE INC. | SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $2,621 | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai | 2024 |
| 2024-04-22 | GENZYME CORPORATION | Sharlin Health And Neurology | $4,564 | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2024 |
| 2024-04-04 | ABBVIE INC. | SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $3,815 | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Ch | 2024 |
| 2024-04-04 | ABBVIE INC. | SHARLIN HEALTH & NEUROLOGY LLC DBA SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $2,315 | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai | 2024 |
| 2024-03-11 | GENZYME CORPORATION | Sharlin Health And Neurology | $3,040 | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2024 |
| 2024-03-11 | GENZYME CORPORATION | Sharlin Health And Neurology | $8,861 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-03-07 | ABBVIE INC. | SHARLIN HEALTH & NEUROLOGY LLC | $732 | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai | 2024 |
| 2024-03-04 | GENZYME CORPORATION | Sharlin Health And Neurology | $14,800 | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa | 2024 |
| 2024-02-22 | PFIZER INC. | SHARLIN HEALTH NEUROSCIENCE RESEARCH CENTER | $675 | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT | 2024 |
| 2024-02-20 | GENZYME CORPORATION | Sharlin Health And Neurology | $13,800 | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2024 |
| 2024-02-12 | GENZYME CORPORATION | Sharlin Health And Neurology | $8,861 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-02-05 | GENZYME CORPORATION | Sharlin Health And Neurology | $10,796 | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2024 |
| 2024-02-01 | ABBVIE INC. | SHARLIN HEALTH & NEUROLOGY LLC | $2,418 | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai | 2024 |
| 2024-01-31 | Eli Lilly and Company | SHARLIN HEALTH AND NEUROLOGY LLC | $2,047 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2024 |
| 2024-01-09 | Eli Lilly and Company | SHARLIN HEALTH AND NEUROLOGY LLC | $278,682 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2024 |
| 2024-01-04 | ABBVIE INC. | SHARLIN HEALTH & NEUROLOGY LLC | $1,686 | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai | 2024 |
| 2024-01-04 | ABBVIE INC. | SHARLIN HEALTH & NEUROLOGY LLC | $231 | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Ch | 2024 |
| 2024-01-03 | GENZYME CORPORATION | Sharlin Health And Neurology | $11,199 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-01-03 | Biogen, Inc. | SHARLIN HEALTH AND NEUROLOGY LLC | $162,712 | A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Bene | 2024 |
| 2023-12-31 | ABBVIE INC. | SHARLIN HEALTH NEUROSCIENCE RESEARCH | $250 | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Ch | 2023 |
| 2023-12-22 | Hoffmann-La Roche Limited | SHARLIN HEALTH AND NEUROLOGY LLC | $14,420 | Fen Ph II RMS | 2023 |
| 2023-12-18 | GENZYME CORPORATION | Sharlin Health And Neurology | $1,913 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2023 |
| 2023-12-04 | ABBVIE INC. | SHARLIN HEALTH & NEUROLOGY LLC DB | $1,677 | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Ch | 2023 |
| 2023-12-04 | ABBVIE INC. | SHARLIN HEALTH & NEUROLOGY LLC DB | $4,453 | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai | 2023 |
| 2023-11-22 | Hoffmann-La Roche Limited | SHARLIN HEALTH AND NEUROLOGY LLC | $1,588 | Fen Ph II RMS | 2023 |
| 2023-11-20 | GENZYME CORPORATION | Sharlin Health And Neurology | $8,000 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2023 |
| 2023-11-16 | PFIZER INC. | 1 | $990 | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT | 2023 |
| 2023-10-30 | GENZYME CORPORATION | Sharlin Health And Neurology | $30,630 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-10-23 | GENZYME CORPORATION | Sharlin Health And Neurology | $16,176 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-10-03 | GENZYME CORPORATION | Sharlin Health And Neurology | $2,150 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2023 |
| 2023-10-03 | GENZYME CORPORATION | Sharlin Health And Neurology | $1,913 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Ozark, MO, county Christian County, MO, state Missouri; placed by its city name.
| Measure | Place (city or town) Ozark, MO | County Christian County, MO | State Missouri |
|---|---|---|---|
| Population B01003 | 22,417 | 92,915 | 6,191,814 |
| Population, 2020 census P1 | 21,284 | 88,842 | 6,154,913 |
| Median age B01002 | 33.8 | 39.2 | 39.0 |
| Under 18 B01001 | 27.9% | 25.1% | 22.3% |
| 65 and over B01001 | 14.6% | 16.7% | 17.9% |
| Households B11001 | 8,408 | 35,142 | 2,508,227 |
| Foreign born B05002 | 4.1% | 2.6% | 4.5% |
| Median household income B19013 | $74,182 | $83,437 | $70,702 |
| Median family income B19113 | $85,938 | $97,213 | $91,360 |
| Per capita income B19301 | $32,257 | $39,805 | $39,695 |
| Poverty rate B17001 | 12.6% | 8.2% | 12.6% |
| Unemployment rate B23025 | 4.3% | 3.4% | 4.0% |
| Civilian labor force B23025 | 11,316 | 46,763 | 3,120,639 |
| Mean commute (minutes) B08013 | 23.5 | 25.5 | 23.5 |
| Bachelor's degree or higher B15003 | 30.7% | 32.7% | 32.4% |
| Housing units B25001 | 8,742 | 36,643 | 2,825,287 |
| Owner-occupied B25003 | 62.6% | 75.9% | 68.1% |
| Renters B25003 | 37.4% | 24.1% | 31.9% |
| Median home value B25077 | $254,800 | $274,900 | $230,300 |
| Median gross rent B25064 | $1,097 | $1,058 | $1,033 |
| White, not Hispanic B03002 | 85.4% | 90.4% | 76.3% |
| Black B03002 | 1.5% | 0.7% | 10.9% |
| Hispanic or Latino B03002 | 6.0% | 3.8% | 5.2% |
| Asian B03002 | 0.8% | 0.8% | 2.1% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Ozark, MO.
Comments